pteridines and mk-1775

pteridines has been researched along with mk-1775 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aspinall, CF; Taylor, SS; Tighe, A; Zheleva, D	1
Frederick, M; Johnson, FM; Kalu, NN; Li, L; Mazumdar, T; Myers, JN; Peng, S; Pickering, CR; Sambandam, V; Shen, L; Singh, R; Tong, P; Wang, J; Zhang, M	1

Other Studies

2 other study(ies) available for pteridines and mk-1775

Article	Year
Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1. Oncotarget, 2015, Nov-03, Volume: 6, Issue:34 Topics: Antimitotic Agents; Cell Cycle Proteins; Cell Line, Tumor; Genetic Heterogeneity; HeLa Cells; Humans; Mitosis; Phosphorylation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Pyrimidines; Pyrimidinones; Small Molecule Libraries	2015
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer letters, 2017, 04-28, Volume: 392 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Checkpoint Kinase 2; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Genotype; Head and Neck Neoplasms; Humans; LIM Domain Proteins; Mice, Nude; Molecular Targeted Therapy; Mutation; Nuclear Proteins; Phenotype; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Pyrimidines; Pyrimidinones; ras Proteins; RNA Interference; Signal Transduction; Smad4 Protein; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Time Factors; Transfection; Tumor Burden; Urea; Xenograft Model Antitumor Assays	2017

Article

Year

Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1.

Oncotarget, 2015, Nov-03, Volume: 6, Issue:34

Topics: Antimitotic Agents; Cell Cycle Proteins; Cell Line, Tumor; Genetic Heterogeneity; HeLa Cells; Humans; Mitosis; Phosphorylation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Pyrimidines; Pyrimidinones; Small Molecule Libraries

2015

Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.

Cancer letters, 2017, 04-28, Volume: 392

Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Checkpoint Kinase 2; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Genotype; Head and Neck Neoplasms; Humans; LIM Domain Proteins; Mice, Nude; Molecular Targeted Therapy; Mutation; Nuclear Proteins; Phenotype; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Pyrimidines; Pyrimidinones; ras Proteins; RNA Interference; Signal Transduction; Smad4 Protein; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Time Factors; Transfection; Tumor Burden; Urea; Xenograft Model Antitumor Assays

2017